A weekly diabetes medication may replace painful daily hormone injections for patients with congenital generalised lipodystrophy (CGL). Early findings suggest that tirzepatide – used for diabetes and ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight ... more evolved or potent medications come to market. At least 27 new GLP-1 drugs are currently ...

Andrew Tenpas, PharmD, RPh, clinical assistant professor at the Texas A&M University Irma Lerma Rangel College of Pharmacy, explains the medications, their benefits and a few drawbacks.

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace ... according to a study in The New England Journal of Medicine. Congenital generalized ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Weight loss drugs catapulted many into a new wellness era, and gave hope to those with diabetes, obesity and who struggled to lose weight. The global anti-obesity drugs market — including the ...